

Resource Summary Report

Generated by [SPARC SAWG](#) on Sep 16, 2026

PRADA

RRID:SCR_011906

Type: Tool

Proper Citation

PRADA (RRID:SCR_011906)

Resource Information

URL: <http://bioinformatics.mdanderson.org/main/PRADA:Overview>

Proper Citation: PRADA (RRID:SCR_011906)

Description: A pipeline to analyze paired end RNA-Seq data to generate gene expression values (RPKM) and gene-fusion candidates.

Abbreviations: PRADA

Synonyms: Pipeline for RNA-Sequencing Data Analysis

Resource Type: software resource

Keywords: unix/linux, bio.tools

Resource Name: PRADA

Resource ID: SCR_011906

Alternate IDs: OMICS_01408, biotools:prada-rnaseq

Alternate URLs: <https://bio.tools/prada-rnaseq>

Record Creation Time: 20220129T080307+0000

Record Last Update: 20260912T195742+0000

Ratings and Alerts

No rating or validation information has been found for PRADA.

No alerts have been found for PRADA.

Data and Source Information

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Urban-Olivares J, et al. (2026) The Copepoda mitogenome as a dynamic evolutionary landscape. PloS one, 21(6), e0350115.

Yu N, et al. (2025) Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones. Experimental & molecular medicine, 57(7), 1567.

Gao Y, et al. (2025) Pan-cancer analysis reveals netrin-1 receptors as potential tumor biomarkers and immune-related therapeutic targets. Scientific reports, 15(1), 44015.

Navas A, et al. (2025) Plasma Proteomic Signature as a Predictor of Age Advancement in People Living With HIV. Aging cell, 24(5), e14468.

Chadwick J, et al. (2025) Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects. Journal of clinical pharmacology, 65(11), 1460.

Singh B, et al. (2025) Developing an electronic surprise question to predict end-of-life prognosis in a prospective cohort study of acute hospital admissions. Clinical medicine (London, England), 25(2), 100292.

Khan ZM, et al. (2024) Development of an Injectable Hydrogel for Histotripsy Ablation Toward Future Glioblastoma Therapy Applications. Annals of biomedical engineering, 52(12), 3157.

Cui Z, et al. (2024) From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis. Frontiers in pharmacology, 15, 1329409.

Shen C, et al. (2023) The development of global creative centers from a regional perspective: A case study of Milan's creative industries. PloS one, 18(4), e0281937.

Murtagh G, et al. (2023) Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions. Journal of the American Heart Association, 12(21), e029574.

Pradat Y, et al. (2023) Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. Cancer discovery, 13(5), 1116.

Lopez-Vinueza C, et al. (2023) Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection. Advances in therapy, 40(6), 2836.

Henriksen PA, et al. (2023) Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. *Circulation*, 148(21), 1680.

Wang M, et al. (2022) Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS^{mutated} lung cancer cells. *Oncology reports*, 48(6).

Mecinaj A, et al. (2021) Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. *Cardio-oncology (London, England)*, 7(1), 33.

Moreno-Carmona M, et al. (2021) How are the mitochondrial genomes reorganized in Hexapoda? Differential evolution and the first report of convergences within Hexapoda. *Gene*, 791, 145719.

Jiang M, et al. (2021) A pan-cancer analysis of molecular characteristics and oncogenic role of hexokinase family genes in human tumors. *Life sciences*, 264, 118669.

Cui Y, et al. (2021) Comprehensive landscape of the renin-angiotensin system in Pan-cancer: a potential downstream mediated mechanism of SARS-CoV-2. *International journal of biological sciences*, 17(14), 3795.

Cole JJ, et al. (2021) Searchlight: automated bulk RNA-seq exploration and visualisation using dynamically generated R scripts. *BMC bioinformatics*, 22(1), 411.

Du Y, et al. (2021) Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR-145/5p/TOP2A axis. *Molecular medicine reports*, 23(6).